Menu

E-Education

E-Education

Watch recordings from our past Educational Events at your leisure anywhere and anytime! Our E-Education has more than 400 presentations that cover important Alpha-1 related topics.

You can also search for more presentations on Vimeo at http://vimeo.com/a1f

This program provides the Alpha-1 Community with access to educational programs from our National Conference and National Education Series.

We gratefully acknowledge all our speakers who volunteered their time and gave permission to record and disseminate their presentations.

Divider
  
What is a Carrier?
Topics : Genetics

Robert A. Sandhaus, MD's, Bio:plus

Robert “Sandy” Sandhaus graduated from Haverford College in Pennsylvania with a degree in molecular biology. He then received a PhD in cell biology and an MD from the State University of New York at Stony Brook. He completed his residency in internal medicine at the Beth Israel Hospital in Boston and a pulmonary fellowship at the University of California San Francisco (UCSF). He was then appointed to the UCSF medical faculty and subsequently joined the medical faulty at the University of Colorado School of Medicine in 1981 where he founded the Alpha1-Antitrypsin Deficiency Program at National Jewish Medical and Research Center in Denver and remains its director. His research throughout his academic career has centered on the role of white blood cell enzymes in the prevention and promotion of lung disease. This work led to a special clinical interest in patients with the genetic deficiency of alpha-1 antitrypsin. In addition to his ongoing academic career. Dr. Sandhaus briefly left medical practice to work in research and development in the biopharmaceutical industry. He ran clinical development programs at Cortech, NeXstar Pharmaceuticals, and Gilead Sciences. Dr. Sandhaus has served on the Boards of Directors of the Alpha-1 Association, the Alpha-1 Foundation, AlphaNet, and the Osteogenesis Imperfecta Foundation. For the past five years, he has been the Executive Vice President and Medical Director of AlphaNet and the Clinical Director of the Alpha-1 Foundation. He is board certified in internal medicine, pulmonary disease, and critical care medicine. He lives in Bow Mar, Colorado.

Importance of Medication Compliance and Proper Use od Inhalers

Micha Campos, MD's, Bio:plus

Michael Campos, M.D. is the Assistant Professor of Clinical Medicine at the Division of Pulmonary and Critical Care Medicine at the University of Miami. He graduated from Cayetano Heredia University in Lima, Peru and did all his postgraduate training at the University of Miami. He is board certified in Internal Medicine, Pulmonary Diseases and Critical Care Medicine. He joined the University of Miami after graduation in 2003 and has been an active researcher in COPD and alpha-1 antitrypsin deficiency, performing both clinical and basic science studies. His principal areas of interest include the pathophysiology of airway disease in Alpha-1, the prevalence of Alpha-1 in Hispanics and outcome studies in Alpha-1. His work has led to several recent publications about Alpha-1 in peer reviewed journals.

COPD Gene Study and Alpha-1 Liver Disease
Speaker : Walsh, , John
Topics : Liver

John Walsh's, Bio:plus

Mr. Walsh is the co-founder, President and CEO of the Alpha-1 Foundation in Miami, Florida. Under his leadership, the organization has become internationally recognized and has invested more than $28 million to support Alpha-1 research and research-related projects, which includes funding grant awards to more than 50 academic institutions in North America and Europe. Mr. Walsh is also co-founder and President of AlphaNet, Inc. a not-for-profit disease management services company providing comprehensive care exclusively for individuals with Alpha-1 Antitrypsin Deficiency. AlphaNet, Inc. currently provides services to 2,500 individuals with Alpha-1 in all 50 states, Puerto Rico and the Virgin Islands. Due to the infrastructure and support provided by the Foundation and AlphaNet, several companies have drugs in development for the treatment of Alpha-1. In 2002 Mr. Walsh’s contribution to pioneering collaboration in orphan drug development was recognized by the FDA with the Commissioner’s Special Citation. Mr. Walsh has an extensive background in business management and government relations; he served three terms on the Advisory Committee on Blood Safety and Availability (1997-2006), is Immediate-Past Chairperson of the National Health Council’s Board of Directors (2005-2006), he is Past Chair and a member of the American Thoracic Society Public Advisory Roundtable (PAR) and was the Presidential Appointee (2004-2005) of the American Thoracic Society’s Board of Directors. He is a member of the American Lung Association National Action Panel on Lung Disease, is on the Advisory Board of the Center for Genetic Research Ethics And Law (CGREAL) at Case Western Reserve University, is a Trustee on the Foundation of the American Thoracic Society (2006-2008) is a member of the US COPD Coalition Executive Committee, Chair of the International COPD Coalition (2006-2008), and a member of the COPD Foundation Board of Directors. He regularly testifies before Congress and advisory groups as a patient advocate. Mr. Walsh was diagnosed with the rare genetic disorder, Alpha-1 Antitrypsin Deficiency, in 1989.

Alpha-1 and the Lungs

Michael Krowka, MD's, Bio:plus

Michael Krowka, MD is a Professor of Medicine, and the Vice Chair of the Division of Pulmonary and Critical Care Medicine at the Mayo Clinic in Rochester, MN, a position he has held since 2001. He also chairs the Mayo Clinic Public Affairs Committee. His chief interest lies in the study of Pulmonary hypertension associated with liver diseases. When asked why he chose to serve on the Alpha-1 Association Board, Dr. Krowka responded, "I have enjoyed my volunteer roles with the Alpha-1 community and physicians since the late 1980's. Most recently, I have served on and chaired the Education Materials Working Group (EMWG) for the Alpha -1 Foundation. As Vice-Chair of the Pulmonary Division at the Mayo Clinic (with clinical interests in pulmonary hypertension, lung volume reduction and lung transplantation), my clinical research derives from daily pulmonary consultation in the Mayo Liver Transplant Clinic, which allows me to see patients with Alpha-1 issues from the liver transplantation perspective. Thus, the ongoing education of pulmonary and hepatology Fellows/Residents regarding alpha-1 antitrypsin deficiency is a continued high priority and daily activity. Finally, I see the educational and research relationships between various lung and liver patient care and professional organizations as an important integration to be fostered via training our young physicians to explore innovative approaches to Alpha-1 patient care. In short, I hope to bring an additional educational emphasis to the Alpha-1 Association Board and contribute ideas that affect both the lung and liver aspects of alpha-1 antitrypsin patient care.

Importance of Exercise

Nasir Sultan Syed, MD's, Bio:plus

Dr. Nasir Syed received his medical degree from Liaquat Medical College, University of Sindh Pakistan. He is Board Certified in Pulmonary Medicine, Internal Medicine and Sleep Medicine. He currently practices at North East Methodist Hospital and North East Baptist Hospital in San Antonio as well as Christus Santa Rosa Hospital in New Braunfels.

Lung Diesease in Alpha-1 Antitrypsin Deficiency
Speaker : Wilson, MD, Jeff
Topics : Lung

Jeff Wilson, MD's, Bio:plus

Jeff Wilson, M.D., is Professor and Program Director of Pulmonary, Department of Internal Medicine at the University of Iowa Hospital and Clinics. He received his undergraduate and medical degree from the University of Iowa. He was twice named "Teacher of the Year" in the Pulmonary Division.

Alpha-1 Deficiency and Liver Disease
Topics : Liver
Regenerative Medicine: Exploring a New Frontier
Topics : Research

Stephen D. Cassivi, MD's, Bio:plus

Stephen Cassivi received his Doctorate in university of Ottawa. He completed his General Surgery residency at the University of Toronto, Canada and is certified by the Royal College of Physicians and Surgeons of Canada and the American Board of Surgery. He completed a subspecialty fellowship in Cardiothoracic Surgery at Washington University in St. Louis, Missouri and is certified by the American Board of Thoracic Surgery. In 1998, Dr. Cassivi was awarded the 1st Annual C. Walton Lillehei Award for research in Lung Transplantation from the American Association for Thoracic Surgery. In 2004, Dr. Cassivi was named Surgical Director of the Lung Transplantation Program at Mayo Clinic in Rochester, Minnesota.

Alpha-1 Liver Disease in Adults & Children

Naim Alkhouri, MD's, Bio:plus

Dr. Naim Alkhouri serves as a Staff Physician with Cleveland Clinic's Children's Hospital and Digestive Disease Institute. He is board certified in internal medicine and pediatrics. He completed his medical degree at the University of Damascus, Damascus, Syria. He is a member of several professional organizations, including the American Association for the Study of Liver Disease, American Gastroenterology Association among others. His specialty interests include nonalcoholic fatty liver disease, viral hepatitis, autoimmune liver disease, end stage liver disease, liver transplantation, and inflammatory bowel disease.

Alpha-1 Lung 101
Topics : Lung

Robert A. Sandhaus, MD's, Bio:plus

Robert “Sandy” Sandhaus graduated from Haverford College in Pennsylvania with a degree in molecular biology. He then received a PhD in cell biology and an MD from the State University of New York at Stony Brook. He completed his residency in internal medicine at the Beth Israel Hospital in Boston and a pulmonary fellowship at the University of California San Francisco (UCSF). He was then appointed to the UCSF medical faculty and subsequently joined the medical faulty at the University of Colorado School of Medicine in 1981 where he founded the Alpha1-Antitrypsin Deficiency Program at National Jewish Medical and Research Center in Denver and remains its director. His research throughout his academic career has centered on the role of white blood cell enzymes in the prevention and promotion of lung disease. This work led to a special clinical interest in patients with the genetic deficiency of alpha-1 antitrypsin. In addition to his ongoing academic career. Dr. Sandhaus briefly left medical practice to work in research and development in the biopharmaceutical industry. He ran clinical development programs at Cortech, NeXstar Pharmaceuticals, and Gilead Sciences. Dr. Sandhaus has served on the Boards of Directors of the Alpha-1 Association, the Alpha-1 Foundation, AlphaNet, and the Osteogenesis Imperfecta Foundation. For the past five years, he has been the Executive Vice President and Medical Director of AlphaNet and the Clinical Director of the Alpha-1 Foundation. He is board certified in internal medicine, pulmonary disease, and critical care medicine. He lives in Bow Mar, Colorado.

Page 31 of 39First   Previous   26  27  28  29  30  [31]  32  33  34  35  Next   Last   

Search


Search


Search

Sponsors

Thank you to our generous program sponsors.

Alphanet
 
CSL Behring
 
EVERSANA
 
Grifols